Acalabrutinib for marginal zone lymphomas – pro

Budde LE, Coleman M, Stevens D, et al. Acalabrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL): Results of a phase 2, multicenter, open-label trial. Presented at ASCO 2022; June 3-7, 2022. Abstract 7549.

Strati P, Coleman M, Champion R, Ma S, Patti C, Levy MY, Lossos IS, Geethakumari PR, Lam S, Calvo R, Higgins K, Budde LE. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. Br J Haematol. 2022 Oct;199(1):76-85.

Categories

Blog Archives